07:00 , Mar 21, 2016 |  BC Week In Review  |  Clinical News

Ameluz: Phase III data

A double-blind, European Phase III trial in 281 patients with 1-3 non-aggressive BCCs of <=2 mm thickness showed that topical BF-200 ALA followed by photodynamic therapy led to complete clearance of all BCCs in 93.4%...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds Myocardin-related transcription factor A (MKL1; MAL; MRTF-A) Mouse studies suggest MRTF-A activation could help treat dermal wounds. In mice with dermal wounds, local application...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

The Jackson Laboratory other research news

Jackson Lab scientists and colleagues published in Cell the identification of the gene defective in mouse slow-wave epilepsy (swe) mutants. These mice exhibit defects in locomotor coordination (ataxia) and have brief periods of behavioral arrest...
07:00 , Mar 21, 2013 |  BC Innovations  |  Targets & Mechanisms

Understanding fibrosis

Researchers at The University of Alabama at Birmingham have identified idiopathic pulmonary fibrosis as a repurposing opportunity for fasudil, a Rho kinase inhibitor that Asahi Kasei Pharma Corp. markets as Eril to treat aneurysm. The...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Pulmonary disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Pulmonary fibrosis Rho kinase; myocardin-related transcription factor A (MKL1; MAL; MRTF-1) Human tissue and mouse studies suggest inhibiting Rho kinase or MKL1 could help...
07:00 , Oct 17, 2011 |  BC Week In Review  |  Company News

Fannin Ltd., Sinclair IS Pharma sales and marketing update

The companies added 10-12 undisclosed generic products from Sinclair's Sinclair IS Pharma Ireland Ltd. subsidiary to a deal granting Fannin commercialization rights to marked drugs Cryogesic ethyl chloride, Mysoline primidone and Variquel terlipressin in Ireland....
07:00 , Jun 9, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Sarcoma Suppressor of variegation 3-9 homolog 1 (SUV39H1; KMT1A) Mouse studies suggest inhibiting KMT1A could help treat rhabdomyosarcoma. In a...
07:00 , Jun 9, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Sarcoma Suppressor of variegation 3-9 homolog 1 (SUV39H1; KMT1A) Mouse studies suggest inhibiting KMT1A could help treat rhabdomyosarcoma. In a...
08:00 , Nov 19, 2009 |  BC Innovations  |  Tools & Techniques

Warming up to lung transplants

Because of structural and inflammatory damage incurred by lungs before and during death, only about 20% of lungs from organ donors are actually useable for transplant. 1 A group at the University of Toronto thinks...
07:00 , Apr 2, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute megakaryoblastic leukemia (AMKL) One twenty-two protein (RBM15; OTT); megakaryocytic acute leukemia (MKL1; MAL); myeloproliferative leukemia virus oncogene (MPL); recombination signal...